AU Patent

AU2011376953B2 — Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof

Assigned to Pharmacyclics LLC · Expires 2017-08-24 · 9y expired

What this patent protects

Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include bendamustine, or a pharmaceutically acceptable salt thereof and an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.

USPTO Abstract

Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include bendamustine, or a pharmaceutically acceptable salt thereof and an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.

Drugs covered by this patent

Patent Metadata

Patent number
AU2011376953B2
Jurisdiction
AU
Classification
—
Expires
2017-08-24
Drug substance claim
No
Drug product claim
No
Assignee
Pharmacyclics LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.